Peptides DB
Research-centric peptide and protocol reference hub
Study 5 of 9Melanotan II literaturePubMed · Case report2026

Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report.

Melanotan II injections can lead to noticeable pigmentation changes in the oral mucosa, which may persist even after stopping the injections.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the melanotan ii corpus
3
Preclinical
6
Observational · this one
0
Open-label
0
Randomised
0
Reviews

Summary and findings

This case report examines the effects of Melanotan II injections on oral mucosa over a three-month period in a patient who self-administered the peptide for tanning. Observations included brown pigmentation on the gingiva and buccal mucosa, with changes noted at one and three months post-injection. The findings contribute to the limited literature on the oral effects of Melanotan II.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as PubMed supplied them

This case report presents a three-month follow-up of a patient who self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect. Melanotan II is an unlicensed synthetic peptide analog belonging to the melanocortin hormone family. It acts primarily by activating melanocortin 1 receptors on melanocytes, stimulating eumelanin production and resulting in skin pigmentation independent of sun exposure. Despite its popularity, particularly through promotion on social media, Melanotan II remains unregulated, and its use is associated with a range of potential adverse effects. During the initial intraoral examination, brown pigmentation was observed on the attached gingiva in both the maxillary and mandibular arches. The lesions were almost symmetrically distributed, with a more intense coloration in the anterior region of the lower jaw. Additional pigmented areas with irregular shapes and poorly defined borders were noted on the left and right buccal mucosa. At the one-month follow-up after discontinuation of the injections, the buccal mucosal pigmentation had nearly disappeared. However, at the three-month follow-up, gingival pigmentation persisted, though with visibly reduced intensity. To date, there is a lack of published data specifically addressing the timeline for resolution of oral pigmentation associated with Melanotan II use, making this case a valuable contribution to the limited existing literature on the subject.

Background

This paper addresses the effects of Melanotan II on oral mucosa, a topic that has not been extensively studied in the literature. Prior research has primarily focused on the systemic effects of Melanotan II, particularly in relation to skin pigmentation. Understanding local effects, such as those on oral tissues, is important for a comprehensive evaluation of the peptide's safety profile.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the Melanotan II corpus

CAssociation of central α-klotho with dopaminergic and melanocortin receptors on feed intake regulation in chicken.europepmc · 2026 · Not reported in abstract.AnimalCLow dose systemic AAV-exendin-4 gene therapy for Prader-Willi syndrome and dietary obesity.europepmc · 2026 · Not reported in abstract.AnimalBFive primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use.europepmc · 2026 · n=1 · Not reported in abstract.HumanCMelanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for foodbiorxiv-preprint · 2022 · n=20 · Not reported in abstract.AnimalDSemantic Scholar search for Melanotan IISemanticScholarDBarbie drug identification: Not a child's play.PubMed · 2024 · 30% purity of Melanotan II.